Researchers at the Hebrew University of Jerusalem say two non-psychoactive compounds derived from cannabis may help treat fatty liver disease, a condition affecting roughly one in three adults worldwide.
The disease, formally known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), is the most common liver disorder globally. Despite its prevalence, treatment options remain limited. “However, this disease does not have a current drug available whatsoever,” said Yossi Tam, a professor at the university’s School of Pharmacy, who led the research.